Category: Resources
-
Video: OLC Pipeline
Video Transcript In our pipeline. We have two products right now. One of them is treating high levels of phosphate in in the blood of patients. And this happens in patients in chronic kidney disease or on dialysis. It’s the end stage renal disease. And the way this drug works is that once food is…
-
AJN: High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders
Stuart M. Spraguea Guru Reddyb Douglas Jermasekc Pramod Guptad aDivision of Nephrology and Hypertension, NorthShore University Health System, Evanston, IL, USA; bPreclinical Research and Development, Unicycive Therapeutics, Inc., Los Altos, CA, USA; cCorporate Strategy, Unicycive Therapeutics, Inc., Los Altos, CA, USA; dPharmaceutical and Business Operations, Unicycive Therapeutics, Inc., Los Altos, CA, USA Abstract Background A…
-
Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate
Vandana Mathur, MD, FASN 1 , ∗ , Michael Walker, PhD 2 ,Steve Hasal, PhD 3 ,Guru Reddy, PhD 3 , Shalabh Gupta, MD 3 1 Mathur Consulting, LLC, Woodside, CA 2 Independent Consultant, Biostatistics, San Diego, CA 3 Unicycive Therapeutics, Inc., Los Altos, CA Abstract Background Phosphate binders (PB) are integral to hyperphosphatemia management…
-
EC Pharmacology and Toxicology: Evaluation of UNI-494 in Acute Kidney Injury Treatment Efficacy When Administered After Ischemia-Reperfusion in a Rat Model
Satya Medicherla1*, Guru Reddy2 and Shalabh Gupta3 1Preclinical Pharmacology, Unicycive Therapeutics, Inc., Los Altos, CA, United States2Preclinical Research and Development, Unicycive Therapeutics, Inc., Los Altos, CA, United States3Chairman of the Board of Directors and CEO, Unicycive Therapeutics, Inc., Los Altos, CA, United States *Corresponding Author: Satya Medicherla, Preclinical Pharmacology, Unicycive Therapeutics, Inc., Los Altos, CA,…
-
Combination Oxylanthanum Carbonate and Tenapanor Synergistically Lowers Urinary Phosphate Excretion in Rats
Satya Medicherla1, PhD; Guru Reddy1, PhD; Pramod Gupta1, PhD; Glenn M. Chertow2, MD, MPH; Shalabh Gupta1, MD 1Unicycive Therapeutics, Inc., Los Altos, CA; 2Stanford University School of Medicine, Stanford, CA Background Methods Results References: 1. Lv JC, Zhang LX. Adv Exp Med Biol. 2019.2. Am J Kidney Dis. 2003.3. King AJ, et al. Sci Transl…
-
UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics
Guru Reddy1, PhD; Sanjay S. Mourya1; Steve Hasal1, PhD; Shalabh Gupta1, MD 1Unicycive Therapeutics, Inc., Los Altos, CA Background Methods Results References 1. Mercado MG, et al., Am Fam Physician. 2019.2. Szeto HH., J Am Soc Nephrol. 2017.3. de Mello AH, et al., Life Sciences. 2018.4. Sharov VG, et al., J Mol Cell Cardiol. 2007.5.…
-
Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats
Satya Medicherla1, PhD; Guru Reddy1, PhD; Shalabh Gupta1, MD 1Unicycive Therapeutics, Inc., Los Altos, CA Background Methods Results References: 1. Kuno A. et.al., Basic Res Cardiol. 2007. Jan.2. Sxeto HH., J Am Soc Nephrol. 2017. Oct.3. de Mello AH. et.al., Life Sci. 2018. Jan.4. Sharov VG. et.al., J Mol Cell Cardiol. 2007. Jan.5. Mishra J.…
-
Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia
Geoff A. Block1, MD; Glenn M. Chertow2, MD, MPH; Guru Reddy3, PhD; Sanjay Mourya3; Martha Block1; Steve J. Hasal3, PhD; Shalabh Gupta3, MD; Pablo E. Pergola4, MD, PhD 1US Renal Care, San Antonio, TX, 78211; 2Stanford University School of Medicine, Stanford, CA, 94305; 3Unicycive Therapeutics, Inc., Los Altos, CA, 94022; 4Renal Associates, PA, San Antonio,…
-
Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function
S. MEDICHERLA1; G. REDDY1; S GUPTA1 1 Unicycive Therapeutics, Inc Background Methods Results References: 1. Cavaillé-Coll M. et al., Am J Transplant. 2013. May. Acknowledgments: Writing support was provided by Xelay Acumen Group, Inc., and funded by Unicycive Therapeutics, Inc.
-
Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats
S. MEDICHERLA1, G. REDDY1, P. GUPTA1, S. GUPTA1 1 Unicycive Therapeutics, Inc. Background Methods Results References: 1.Lv JC, et al., Adv Exp Med Biol. 2019. Aug.2.K/DOQI clinical practice guidelines. Am J Kidney Dis. 2003. Oct.3.XPHOZAH (tenapanor) tablets, for oral use [prescribing information]. Ardelyx. 2023.4.King AJ, et al., Am J Physiol Renal Physiol. 2021. Jan. Arenas…
